Last reviewed · How we verify

Biological: Solrikitug low dose — Competitive Intelligence Brief

Biological: Solrikitug low dose (Biological: Solrikitug low dose) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-1β inhibitor. Area: Inflammatory diseases.

phase 2 IL-1β inhibitor IL-1β Inflammatory diseases Biologic Live · refreshed every 30 min

Target snapshot

Biological: Solrikitug low dose (Biological: Solrikitug low dose) — Uniquity One (UNI). Solrikitug is a low-dose biological drug that targets the IL-1β pathway.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Biological: Solrikitug low dose TARGET Biological: Solrikitug low dose Uniquity One (UNI) phase 2 IL-1β inhibitor IL-1β
Canakinumab Injection canakinumab-injection Pfizer marketed Monoclonal Antibody IL-1β
Ilaris® Ilaris® AO GENERIUM marketed IL-1β inhibitor (monoclonal antibody) IL-1β (Interleukin-1 beta)
Ziltivekimab B Ziltivekimab B Novo Nordisk A/S phase 3 IL-1β inhibitor IL-1β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-1β inhibitor class)

  1. Uniquity One (UNI) · 2 drugs in this class
  2. Novo Nordisk A/S · 1 drug in this class
  3. SCRI Development Innovations, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biological: Solrikitug low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-solrikitug-low-dose. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: